EXHIBIT 23.5
Published on July 6, 2020
Exhibit 23.5
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated July 1, 2020, with respect to the financial statements of Ocuphire Pharma, Inc. included in the Registration
Statement (Form S-4) and related prospectus of Rexahn Pharmaceuticals, Inc.
/s/ Ernst & Young LLP
Detroit, Michigan
July 6, 2020